Non-Alcoholic Steatohepatitis (NASH) Industry Revenue to Reach $18.55 Billion by 2029 with CAGR of 32.3% (2025–2029)
Claim 20% Off With Code ONLINE20 – Explore Market Reports Covering Trade Trends, Regulatory Changes, and Growth Insights
What Is the Potential Market Growth Rate of the Non-Alcoholic Steatohepatitis (NASH) Market?
The non-alcoholic steatohepatitis (NASH) market size has grown exponentially in recent years. It will grow from $4.5 billion in 2024 to $6.06 billion in 2025 at a compound annual growth rate (CAGR) of 34.7%. The growth in the historic period can be attributed to rising prevalence of NASH, obesity epidemic, growing awareness and diagnoses, shift in lifestyle and dietary patterns, healthcare infrastructure development.
The non-alcoholic steatohepatitis (NASH) market size is expected to see exponential growth in the next few years. It will grow to $18.55 billion in 2029 at a compound annual growth rate (CAGR) of 32.3%. The growth in the forecast period can be attributed to advancements in NASH drug development, increasing NASH screening initiatives, rising healthcare expenditure, collaborative research efforts, government support and regulations. Major trends in the forecast period include focus on lifestyle interventions and patient education, increased collaboration in clinical research, regulatory advancements and pathway designations, integration of artificial intelligence in diagnosis and monitoring.
Claim your free report sample now:
Who Are the Major Contributors to the Non-Alcoholic Steatohepatitis (NASH) Market Growth?
The rising cases of obesity is driving the demand for the non-alcoholic steatohepatitis (NASH) market going forward. Obesity is an aberrant or excessive fat build-up that poses a health concern, as well as body weight that is higher than what is deemed healthy or typical for a person of a specific height. As non-alcoholic fatty liver disease has become more prevalent due to the rising obesity pandemic, NASH may become the most widespread cause of severe liver disease in the ensuing decades, therefore, driving need for NASH treatment and related drugs. For instance, in March 2024, according to the World Health Organization (WHO), a UK-based international public health organization, in 2022, approximately 2.5 billion adults aged 18 and older were classified as overweight, with 890 million of them living with obesity. Therefore, the rise in the cases of obesity will drive the growth of the non-alcoholic steatohepatitis (NASH) market.
What Are the Key Segments in the Non-Alcoholic Steatohepatitis (NASH) Market?
The non-alcoholic steatohepatitis (nash) market covered in this report is segmented –
1) By Type: Solid, Liquid
2) By Product: Vitamin E and Pioglitazone, Ocaliva, Elafibranor, Selonsertib and Cenicriviroc, Other Products
3) By Disease Cause: Hypertension, Heart Disease, High Blood Lipid, Type 2 Diabetes, Obesity
4) By Sales Channel: Hospital Pharmacy, Retail Pharmacy, Online Provider
5) By Application: Oral, Parenteral
Subsegments:
1) By Solid: Tablets, Capsules, Other Solid Dosage Forms
2) By Liquid: Oral Solutions, Syrups, Injectable Solutions, Other Liquid Dosage Forms
What Are the Future Trends Forecasted for the Non-Alcoholic Steatohepatitis (NASH) Market?
Major companies operating in the non-alcoholic steatohepatitis (NASH) market are developing thyroid hormone receptor-beta (THR-beta) agonists to enhance liver metabolism, reduce liver fat accumulation, and improve liver function. Thyroid hormone receptor-beta (THR-beta) agonists are compounds that selectively activate the thyroid hormone receptor-beta subtype, which is a key receptor involved in the regulation of metabolism, growth, and development. For instance, in March 2024, the Food and Drug Administration, a US-based regulatory body, approved Rezdiffra (resmetirom), a thyroid hormone receptor-beta agonist as the first treatment for adults with noncirrhotic NASH with moderate to advanced liver scarring (fibrosis). By selectively activating the THR-beta receptor, Rezdiffra helps regulate lipid metabolism, leading to a reduction in intrahepatic triglycerides and overall liver fat accumulation.
Who Are the Prominent Players in theNon-Alcoholic Steatohepatitis (NASH) Market?
Major companies operating in the non-alcoholic steatohepatitis (NASH) market include NGM Biopharmaceuticals Inc., Novartis AG, AstraZeneca plc., GlaxoSmithKline plc., F. Hoffmann-La Roche AG, The Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Novo Nordisk A/S, Genfit SA, Cadila Pharmaceuticals Ltd., Intercept Pharmaceuticals Inc., Enanta Pharmaceuticals Inc., Blade Therapeutics Inc., Galmed Pharmaceuticals Inc., Immuron Limited, Terns Pharmaceuticals Inc., Tobira Therapeutics Inc., Arena Pharmaceuticals Inc., Galectin Therapeutics Inc., Viking Therapeutics, Madrigal Pharmaceuticals Inc., Cirius Therapeutics, Akero Therapeutics Inc., Echosens.
Get the full non-alcoholic steatohepatitis (nash) market report here:
Which Regions Are Forecasted to Experience the Fastest Growth in the Non-Alcoholic Steatohepatitis (NASH) Market?
North America was the largest region in the non alcoholic steatohepatitis (NASH) market share in 2024. The regions covered in the non-alcoholic steatohepatitis (nash) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment